Fusen Pharmaceutical replaces KPMG with CCTH after audit fee dispute

  • Fusen Pharmaceutical replaced auditor KPMG with CCTH effective Dec. 24, 2025 for audit of FY2025 financial statements.
  • Change followed fee dispute, with KPMG proposing RMB 4.5 million versus agreed CCTH fee of HK$ 3 million.
  • KPMG cited higher staff costs, tighter regulatory scrutiny, and added audit work tied to revenue recognition, receivables testing, and a 2025 disposal transaction.
  • Audit committee said KPMG confirmed no unresolved audit issues or disagreements beyond audit fees.
  • CCTH is scheduled to complete audit work by March 31, 2026 in time for annual results release.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260410-12102472), on April 10, 2026, and is solely responsible for the information contained therein.